Moderna announced plans to reduce its expenses by more than $1 billion by 2027 as it transitions from its COVID-19 business. The biotech company aims to secure ten new product approvals by 2027, including vaccines for RSV and a flu-COVID combination shot. Moderna will pause or discontinue certain pipeline products, trimming its research and development spending. The company also highlighted its potential vaccines for cancer and latent viruses, which could drive revenue growth. Moderna projects 2025 revenue between $2.5 billion and $3.5 billion and expects a 25% annual growth rate as new products launch by 2026.